Akeso

Akeso presented preclinical data for AK135, a novel IL-1RAP targeting antibody, at SITC 2025, demonstrating effective blockade of three key inflammatory pathways.

The phase 3 COMPASSION-15 trial's final analysis confirms cadonilimab plus XELOX chemotherapy significantly improved overall survival to 13.9 months versus 11.1 months with chemotherapy alone in first-line treatment of advanced gastric/GEJ adenocarcinoma.

Akeso's commercial sales surged 49.20% to RMB 1,401.6 million in the first half of 2025, driven by expanded indications and NRDL inclusion for its bispecific antibodies.

Ivonescimab, a PD-1/VEGF bispecific antibody, achieved a 48% reduction in progression-free survival risk compared to chemotherapy in EGFR-mutated NSCLC patients.

AstraZeneca is negotiating with Summit Therapeutics for a potential $15 billion licensing deal for ivonescimab, an experimental lung cancer drug that has shown promising results in late-stage trials.

Akeso has grown from a $3 million startup founded in 2012 to a $15 billion global biotech company, becoming a leader in bispecific antibody innovation with over 3,400 employees.

Bristol Myers Squibb will pay BioNTech $1.5 billion upfront plus $2 billion in anniversary payments through 2028 for a 50% partnership in BNT327, a bispecific antibody targeting both PD-L1 and VEGF proteins.

• Pfizer has completed a record-breaking $6 billion acquisition deal with Chinese biopharmaceutical company 3SBio, energizing China's innovative drug industry and potentially driving further valuations upward. • RemeGen successfully raised HK$796 million through a premium placement, demonstrating strong investor confidence following the successful out-licensing of its RC18 asset. • The transactions highlight the growing momentum in China's biotech sector, with 3SBio's valuation expected to continue rising while competitor Akeso may face downward pressure. • China's 11th batch of national Volume-Based Procurement (VBP) rules are expected to include optimizations balancing competitive bidding prices with drug quality standards.

Summit Therapeutics reported statistically significant improvement in progression-free survival for ivonescimab plus chemotherapy versus BeiGene's Tevimbra combination in advanced squamous non-small cell lung cancer.

Akeso has received FDA approval for its first internally developed cancer therapeutic, marking a significant milestone for the Chinese biopharmaceutical company's expansion into the US market.